SHARESIFT
Healthcare · data ~15-min delayed
5,643 JPY -1.54%
| Price | 5,643 JPY |
| Day change | -1.54% |
| Market cap | 9.01T |
| 52-week range | 4,102 – 6,033 |
| P/E (trailing) | — |
| Dividend yield | 3.62% |
| Payout ratio | 167.17% |
| Return on equity | -2.26% |
| Debt / equity | 73% |
| Beta | 0.10 |
| Sector | Healthcare |
| Value score | 44 / 100 |
How the value score is calculated: 13 published tests, weighted to 100.
Takeda Pharmaceutical Company Limited (4502.T) scores 44/100 on this site's value model, a middling reading with some valuation measures favourable and others not. It is classified in Healthcare. The dividend yield is 3.62%, paid from 167% of earnings. Return on equity is -2%, with debt at 73% of equity. On its filings it passes 4 of the nine Piotroski checks, a mixed picture. Its Altman Z-Score places it in the distress zone. These are automated readings of reported figures, not a recommendation.
Piotroski F-Score 4 / 9 — nine pass/fail checks on profitability, leverage and efficiency, comparing the latest financial year with the one before.
Altman Z-Score 1.14 — Distress zone. The model was built for manufacturers and scores lenders and capital-heavy businesses low by construction, so read this alongside the balance sheet.
Updated · prices ~15-min delayed, fundamentals as last reported
Open full interactive analysis →See how it ranks: Japan stocks by value score
Value scoring · Piotroski F-Score · Altman Z · technicals · dividends — free, no sign-up.